Inhibition of tumor cell growth and angiogenesis by 7-Aminoalkoxy-4- aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors

European Journal of Medicinal Chemistry

Volumn 79, Issue , 2014, Pages 369-381

  Ravez, Séverine ^a,b   Barczyk, Amélie ^a,b   Six, Perrine ^a,b   Cagnon, Aurélie ^a,b   Garofalo, Antonio ^a,b   Goossens, Laurence ^a,b   Depreux, Patrick ^a,b  

^a UNIV LILLE   (France)

^b Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

Anti angiogenic agents; c Kit; Cancer; Multi kinase inhibitors; PDGFR ; VEGFR

Indexed keywords

4 CHLORO 6 METHOXY 7 PIPERIDINOETHOXYQUINAZOLINE; 4 CHLORO 6 METHOXY 7 PIPERIDINOPROPOXYQUINAZOLINE; 4 CHLORO 6 METHOXY 7 PYRROLIDINOETHOXYQUINAZOLINE; 6 METHOXY 7 PIPERIDINOETHOXYQUINAZOLIN 4 ONE; 6 METHOXY 7 PIPERIDINOPROPOXYQUINAZOLIN 4 ONE; 6 METHOXY 7 PYRROLIDINOETHOXYQUINAZOLIN 4 ONE; 7 AMINOALKOXY 4 ARYLOXY UREA DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CEDIRANIB; METHYL 2 AMINO 4 PIPERIDINOETHOXY 5 METHOXYBENZOATE; METHYL 2 AMINO 4 PIPERIDINOPROPOXY 5 METHOXYBENZOATE; METHYL 2 AMINO 4 PYRROLIDINOETHOXY 5 METHOXYBENZOATE; METHYL 2 NITRO 4 PIPERIDINOETHOXY 5 METHOXYBENZOATE; METHYL 2 NITRO 4 PIPERIDINOPROPOXY 5 METHOXYBENZOATE; METHYL 2 NITRO 4 PYRROLIDINOETHOXY 5 METHOXYBENZOATE; METHYL 3 METHOXY 4 PIPERIDINOETHOXYBENZOATE; METHYL 3 METHOXY 4 PIPERIDINOPROPOXYBENZOATE; METHYL 3 METHOXY 4 PYRROLIDINOETHOXYBENZOATE; N (3 BROMO PHENYL) N' (3 CHLORO 4 HYDROXYPHENYL)UREA; N (3 BROMO PHENYL) N' (3 METHYL 4 HYDROXYPHENYL)UREA; N (3 BROMO PHENYL) N' (4 HYDROXYPHENYL)UREA; N (3 BROMO PHENYL) N' [4 [(6 BUTOXY 7 DIETHYLAMINOETHOXYQUINAZOLIN 4 YL)OXY]PHENYL]UREA; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; VANDETANIB; VASCULOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UREA; VASCULOTROPIN RECEPTOR 2;

ALKYLATION; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IC 50; PROSTATE CANCER; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HT 29 CELL LINE; MCF 7 CELL LINE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; UREA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84898947103     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.04.007     Document Type: Article

References (23)

1. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nature Reviews Cancer 11 2011 393 410
2. P.M. Hoff, and K.K. Machado Role of angiogenesis in the pathogenesis of cancer Cancer Treatment Reviews 38 2012 825 833
3. E.M. Bridges, and A.L. Harris The angiogenic process as a therapeutic target in cancer Biochemical Pharmacology 81 2011 1183 1191
4. A. Hoeben, B. Landuyt, M.S. Highley, H. Wildiers, A.T. Van Oosterom, and E.A. De Bruijn Vascular endothelial growth factor and angiogenesis Pharmacological Reviews 56 2004 549 580 (Pubitemid 39658463)
5. Z.K. Otrock, J.A. Makarem, and A.I. Shamseddine Vascular endothelial growth factor family of ligands and receptors: review Blood Cells Molecules and Diseases 38 2007 258 268 (Pubitemid 46518176)
6. S. Koch, S. Tugues, X. Li, L. Gualandi, and L. Claesson-Welsh Signal transduction by vascular endothelial growth factor receptors Biochemical Journal 437 2011 169 183
7. K.J. Gotink, and H.M.W. Verheul Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13 2010 1 14
8. S. Tugues, S. Koch, L. Gualandi, X. Li, and L. Claesson-Welsh Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer Molecular Aspects of Medicine 38 2011 11 88
9. J.H. Strickler, and H.I. Hurwitz Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer Oncologist 17 2012 513 524
10. S. Rogosin, and A.B. Sandler Beyond bevacizumab: antiangiogenic agents Clinical Lung Cancer 13 2012 326 333
11. F. Musumeci, M. Radi, C. Brullo, and S. Schenone Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors Journal of Medicinal Chemistry 55 2012 10797 10822
12. Y.G. Najjar, and B.I. Rini Novel agents in renal carcinoma: a reality check Therapeutic Advances in Medical Oncology 4 2012 183 194
13. S. Kunnakkat, M. Mathew, and A. Narayana Antiangiogenic therapy in the management of brain tumors: a clinical overview Cancer Chemotherapy and Pharmacology 70 2012 353 363
14. M.W. Welker, and J. Trojan Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives World Journal of Gastroenterology 17 2011 3075 3081
15. A. Garofalo, L. Goossens, A. Lemoine, A. Farce, Y. Arlot, and P. Depreux Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer Journal of Enzyme Inhibition and Medicinal Chemistry 25 2010 158 171
16. A. Garofalo, L. Goossens, P. Six, A. Lemoine, S. Ravez, A. Farce, and P. Depreux Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors Bioorganic & Medicinal Chemistry Letters 21 2011 2106 2112
17. A. Garofalo, A. Farce, S. Ravez, A. Lemoine, P. Six, P. Chavatte, L. Goossens, and P. Depreux Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors Journal of Medicinal Chemistry 55 2012 1189 1204
18. A. Garofalo, L. Goossens, A. Lemoine, S. Ravez, P. Six, M. Howsam, A. Farce, and P. Depreux [4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors Medicinal Chemistry Communications 2 2011 65 75
19. D.E. Thurston, D.S. Bose, A.S. Thompson, P.W. Howard, A. Leoni, S.J. Croker, T.C. Jenkis, S. Neidle, J.A. Hartley, and L.H. Hurley Synthesis of sequence-selective C8-linked pyrrolo[2,1-c][1,4]benzodiazepine DNA interstrand cross-linking agents Journal of Organic Chemistry 61 1996 8141 8147 (Pubitemid 26400930)
20. M. Robba, J.M. Leconte, and M. Cugon de Sevricourt Thié nopyrimidine. I. Etude de l'oxo-4-dihydro-3,4-thiéno[2,3-d]pyrimidine Bulletin de la Societe Chimque de France 10 1970 3630 3636
21. A.L. Ruchelman, P.J. Houghton, N. Zhou, A. Liu, L.F. Liu, and E.J. Lavoie 5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance Journal of Medicinal Chemistry 48 2005 792 804 (Pubitemid 40209101)
22. H.M.I. Osborn, and N.A.O. Williams Development of tyrosinase labile protecting groups for amines Organic Letters 6 2004 3111 3113 (Pubitemid 39233132)
23. M. Desroses, G. Laconde, P. Depreux, and J.P. Henichart Synthesis of unsymmetrical dialkoxy quinazolines Organic Preparations and Procedures International 36 2004 445 452 (Pubitemid 39531415)